Table 2 Overview of the study-specific parameters of the included studies. Values are presented as the mean values ± standard deviation, mean values (range) or percentages
Author, year | Treatment | Country | No. of patients | Study type | Subjects mean age in years | Time since Tx | Female (%) | Control group for OHRQoL | |
|---|---|---|---|---|---|---|---|---|---|
HC | preTx | ||||||||
Segura-Saint-Gerons et al. [22] | HTx | Spain | 150 | Monocentric cross-sectional | 54.94 ± 14.56 | 30.7% < 5 years, 32% 5–10 years, 37.3% > 10 years | 21.3% | No | No |
Schmalz et al. [23] | KTx | Germany | 39 | Multicentric cross-sectional | 56.51 ± 11.56 | n/a | 51.3% | Yes, n = 91, age: 58.31 ± 9.91 years, 65.9% female | Yes, HD n = 87, 37.9% Female, age: 60.98 ± 14.01 |
Schmalz et al. [24] | LuTx | Germany | 60 | Monocentric cross-sectional | 54.03 ± 9.97 | > 6 years: 58.3% | 50% | Yes, n = 70, age: 55.44 ± 8.54 years, 63% female | No |
Schmalz et al. [25] | LTx | Germany | 47 | Monocentric cross-sectional | 46.6 ± 12.6 | 4.7 ± 3.9 years | 42.6% | Yes, n = 75, 58.7% female, 57.1 ± 9.9 | Yes, preLTx n = 24, 41.7% female, 54.4 ± 9.5 years |
Ruokonen et al. [21] | KTx | Finland | 51 | Prospective observational | 61 (31–86) | 7.1 (1–11) years | 33% | No | Yes, predialysis n = 144, 32.6% female, age 23–83 years |
Schmalz et al. [26] | HTx | Germany | 104 | Monocentric cross-sectional | 55.26 ± 12.16 | 6.8 ± 5.16 years | 25% | No | Yes, HI n = 82, 54.90 ± 11.14 years, 15.9% female |
Oduncuoğlu et al. [27] | KTx | Turkey | 64 | Monocentric cross-sectional | 37.90 ± 10.30 | 1 year 18.8%, < 1–5 years 45.3%, > 5 years 35.9% | 31.2% | Yes, n = 61, 37.10 ± 13.41, 65.6% female | Yes, HD n = 63, 40.98 ± 9.99 years, 38.1% female |